IQVIA Holdings Inc. Q1 2026 Earnings Call Summary

9 hours ago 1

Moby Intelligence

Tue, May 5, 2026 astatine 11:51 AM CDT 3 min read

Organic gross maturation accelerated significantly, with Commercial Solutions doubling and R&D Solutions tripling its maturation complaint twelvemonth implicit year.
Commercial show was bolstered by grounds pipeline levels and the highest maturation successful Analytics and Consulting successful 3 years, driven by caller cause motorboat activity.
The institution has transitioned to an 'AI-native' operating model, deploying 192 specialized agents crossed 64 usage cases to thrust operational ratio and lawsuit insights.
R&D Solutions maturation was supported by faster-than-expected backlog conversion and coagulated nett work interest bookings, contempt a little book-to-bill ratio caused by pass-through mix.
Management attributes the beardown request situation to rising proceedings complexity and the request for clients to physique AI-ready information foundations to modernize show reporting.
Strategic repositioning done a caller conception reporting operation effectual January 1, 2026, aims to amended align offerings with objective and commercialized marketplace dynamics.

Full-year 2026 gross guidance assumes astir 150 ground points of publication from acquisitions and 100 ground points of overseas speech tailwinds.
Management raised adjusted diluted EPS guidance for the afloat year, reflecting assurance successful productivity programs and operational borderline expansion.
The $34.2 cardinal backlog includes $8.9 cardinal expected to person to gross wrong the adjacent 12 months, representing astir 8% maturation implicit the anterior year.
EBP backing reached $25 cardinal successful Q1, astir treble the anterior year, which absorption views arsenic a starring indicator for aboriginal objective proceedings awards and backlog growth.
Future R&D request is expected to beryllium fueled by ample pharma utilizing AI to place much discovery-stage targets, necessitating accrued CRO capableness for upcoming trials.

The Q1 book-to-bill ratio of 1.04 was impacted by an unusually debased premix of pass-through bookings, which were astir one-third little than the historical average.
EBITDA margins saw a 60 ground constituent contraction successful Q1 owed to non-operational headwinds from FX and pass-throughs, though operational productivity remained strong.
Management flagged that portion the situation is stabilizing, ample pharma sponsors stay much deliberate successful superior deployment compared to pre-disruption speeds.
A strategical determination promotion statement with Pfizer covering 23 European countries highlights a displacement toward AI-supported exertion successful commercialized intelligence.